Eduardo Arce Parellada, General Manager at Sanofi Pasteur Mexico until March 2017, explains the positive impact that the vaccine against Dengue could generate for the national health system and showcases the positioning of Sanofi Pasteur as the partner of choice for the government in vaccinology, based on its local R&D and manufacturing capabilities.
In December 2015, Mexico approved Sanofi Pasteur’s dengue vaccine, marking the first time a dengue vaccine has been licensed for use in a country, and therefore a major milestone in the history of vaccinology. How has this experience been for you as General Manager for Sanofi Pasteur in Mexico?
"The discovery of [the Dengue] vaccine has taken more than 20 years of development in our R&D centers. Indeed, Mexico participated in the development of the vaccine from phase I to phase III and it is worth mentioning that, on December 9th 2015, Mexico was the first country in the world to have the Dengue vaccine registered."
